Patent Application
20110189666
This relates to the field of genetic engineering, and more specifically, to a nucleic acid probe set useful for analyzing a nucleic acid and a method for using the same.
In detection methods of target nucleic acids, single-stranded nucleic acid probes that specifically hybridize to the target nucleic acids are widely used. As one of these detection methods of target nucleic acids, said detection methods making use of the single-stranded nucleic acid probes, there is the Q-probe (Quenching Probe) method. According to this Q-probe method, such a nucleic acid probe is labeled with a fluorescent substance. When this nucleic acid probe hybridizes to a target nucleic acid, fluorescence is quenched under the action of guanine in the target nucleic acid. Upon dissociation of the nucleic acid probe from the target nucleic acid, fluorescence is re-emitted. The Q-probe method utilizes this phenomenon. The Q-probe method has excellent advantages in that the structure of the probe is simple, no trial-and-error approach is needed for the designing of the probe, and highly-accurate results can be obtained (see, for example, Patent Document 1 and Patent Document 2).
As such a conventional, single-stranded nucleic acid probe, however, a fluorescently-labeled nucleic acid probe having a different base sequence has to be prepared specifically for every target nucleic acid to be detected. Such a fluorescently-labeled nucleic acid probe is accompanied by problems that it is relatively costly and its synthesis requires a long time, and therefore, involves problems that an experiment making use of it is costly and requires a lot of time in preparation.
Objects of the present invention are, therefore, to provide a nucleic acid probe, which can solve the above-mentioned problems of the conventional technology and can be prepared in a short time and economically, and also a method for using the same.
The above-described objects can be achieved by the present invention to be described hereinafter. Described specifically, the present invention provides a nucleic acid probe set comprising (A) one or two fluorescent probe or probes, each of which is formed of an oligonucleotide including (a) a nucleotide labeled with (d) a fluorescent substance, and (B) a binding probe formed of an oligonucleotide having (b1) one or two fluorescent probe binding region or regions, to which the fluorescent probe or probes (A) can hybridize, and (b2) a target nucleic acid binding region, which can hybridize to a target nucleic acid (C), wherein the nucleic acid probe set is designed such that, when the fluorescent probe or probes (A) hybridizes or hybridize to the fluorescent probe binding region or regions (b1) and the target nucleic acid (C) hybridizes to the target nucleic acid binding region (b2), guanine in a nucleic acid, said nucleic acid including the target nucleic acid (C), and the fluorescent substance (d) labeled on the nucleotide (a) interact with each other to change a fluorescent character of the fluorescent substance (d).
In the above-described nucleic acid probe set according to the present invention, it is preferred that the fluorescent substance (d) is any one selected from the group consisting of fluorescein, fluorescein-4-isothiocyanate, tetrachlorofluorescein, hexachlorofluorescein, tetrabromosulfonefluorescein, EDANS, 6-JOE, Alexa Fluor 488, Alexa Fluor 532, Pacific Blue, rhodamine 6G, carboxyrhodamine 6G, tetramethylrhodamine, carboxytetramethylrhodamine and BODIPY-FL; that the one or two fluorescent probe or probes (A) each comprise an oligonucleotide labeled at a 5′-terminal nucleotide or 3′-terminal nucleotide thereof with the fluorescent substance (d); that the one or two fluorescent probe or probes (A) are each 5 to 50 bases long; and that the target nucleic acid binding region (b2) is 5 to 60 bases long.
The present invention also provides a method for detecting a target nucleic acid, which comprises the following steps (1) to (4):
(1) hybridizing the nucleic acid probe set according to the present invention and the target nucleic acid (C) with each other,
(2) then measuring the fluorescence intensity of a hybridized complex of the nucleic acid probe set and target nucleic acid (C),
(3) conducting the steps (1) and (2) by changing a ratio of the nucleic acid probe set to the target nucleic acid, and
(4) comparing the fluorescence intensities obtained from the steps (2) and (3); and also
a real-time PCR method, which comprises using the nucleic acid probe according to the present invention.
The present invention further provides a method for analyzing a nucleic acid for a base sequence polymorphism, which comprises the following steps (1) to (4):
(1) hybridizing the nucleic acid probe set according to the present invention and a target nucleic acid (C) with each other,
(2) then measuring a temperature dependence of fluorescence intensity with respect to a hybridized complex of the nucleic acid probe set and target nucleic acid (C),
(3) conducting the steps (1) and (2) by using another nucleic acid in place of the target nucleic acid, and
(4) comparing the temperature dependences of fluorescence intensity as obtained from the steps (2) and (3).
The present invention still further provides a method, which comprises conducting a melting curve analysis on a complex of the nucleic acid probe set according to the present invention and a target nucleic acid (C).
The present invention even still further provides the nucleic acid probe set according to the present invention, wherein the fluorescent probe (A) consists of two fluorescent probes, which have different base sequences and are labeled with different fluorescent substances, respectively, and the binding probe (B) has two fluorescent probe binding regions having different base sequences, and an ABC-PCR method, which comprises using the nucleic acid probe set.
As nucleic acid probes for use in various analysis methods of nucleic acids, it has conventionally been needed to prepare, specifically for every target nucleic acid to be analyzed, one labeled with a costly fluorescent substance. According to the present invention, however, it is unnecessary to prepare a nucleic acid probe, which is labeled with a costly fluorescent substance, specifically for every target nucleic acid. Compared with such conventional nucleic acid probes, nucleic acid probes can, therefore, be provided economically and in a short time.
Best modes for carrying out the present invention will next be described with reference to drawings. It is to be noted that in the present invention, the hybridized complex of the fluorescent probe (A) and binding probe (B) may be called “the nucleic acid probe complex”.
Further, the term “nucleotide” as used herein means a monomer of a deoxyribonucleotide or ribonucleotide, and the term “oligonucleotide” as used herein means an oligomer formed from a nucleotide. This oligomer may be formed from only a deoxyribonucleotide or a ribonucleotide, or may contain both of them.
The term “target nucleic acid” as used herein means the region of a base sequence that specifically hybridizes with the target nucleic acid binding region (b2) in the binding probe (B) which constitutes the nucleic acid probe set according to the present invention, and shall be construed that it may include a portion or portions of one or more of various nucleic acids or genes in some instances. The target nucleic acid can be of any type, and DNA, RNA, LNA, PNA artificially-modified nucleic acids, and the like can be mentioned.
Examples of the nucleic acid probe set according to the present invention are shown in
The one or two fluorescent probe or probes (A), which constitutes or constitute the nucleic acid probe set according to the present invention and may hereinafter be called simply “the fluorescent probe (A)”, are each the oligonucleotide including the nucleotide (a) labeled with the fluorescent substance (d). No particular limitation is imposed on the base sequence of the fluorescent probe (A) insofar as it can hybridize with the fluorescent probe binding region (b1) in the binding probe (B). The same fluorescent probe can, therefore, be always used irrespective of the type of a target nucleic acid to be detected or analyzed. As the fluorescent probe (A) that constitutes the nucleic acid probe set according to the present invention is not required to have a base sequence corresponding to a specific target nucleic acid as mentioned above, the use of the nucleic acid probe set according to the present invention for the analysis of a target nucleic acid has an advantage in that it is no longer needed to prepare a fluorescent probe, which has a costly fluorescent substance, specifically for the target nucleic acid to be detected or analyzed.
On the other hand, the binding probe (B) that also constitutes the nucleic acid probe set according to the present invention is the oligonucleotide having the one or two fluorescent probe binding region or regions (b1) and the target nucleic acid binding region (b2). The one or two fluorescent probe binding region or regions (b1) hybridizes or hybridize with the fluorescent probe or probes (A), and may hereinafter be called simply “the fluorescent probe binging region (b1)”. The target nucleic acid binding region (b2) hybridizes with the target nucleic acid (C).
The nucleic acid probe set according to the present invention as shown in
The guanine may exist either inside or outside the base sequence region of the target nucleic acid, insofar as it exists in the nucleic acid that includes the target nucleic acid. When the guanine exists in the base sequence of the target nucleic acid and forms a base pair with cytosine in the hybridized binding probe (B), the interaction between the fluorescent substance (d) and the guanine is somewhat weaker although no particular problem arises. When the guanine forms no base pair for such a reason that the guanine exists outside the base sequence region of the target nucleic acid, on the other hand, the interaction between the fluorescent substance (d) and the guanine is facilitated. Accordingly, the latter situation is more preferred.
Referring next to
The fluorescent probe (A) is now assumed to have hybridized with the binding probe (B). Base pairs are formed between the fluorescent probe binding region (b1) and the fluorescent probe (A). A nucleotide, which exists in the fluorescent probe binding region (b1) and is closest to the target nucleic acid binding region (b2), will hereinafter be called “the nucleotide α”. A nucleotide, which exists in the fluorescent probe (A) and forms a base pair with the nucleotide α will be designated as “β”. The distance (β-a) between the nucleotide β and the nucleotide (a) labeled with the fluorescent substance will be designated as “X”. In
On the other hand, base pairs are formed between the target nucleic acid (C) and the target nucleic acid binding region (b2). A nucleotide which exists in the target nucleic acid binding region (b2) and is closest to the nucleotide α will be designated as “the nucleotide γ”. The distance (γ-α) between the nucleotide γ and the nucleotide α will be designated as “Y” expressed in terms of the number of base(s). In
The binding probe (B) and the target nucleic acid (C) are now assumed to have hybridized with each other. A nucleotide in the target nucleic acid (C), said nucleotide forming a base pair with the nucleotide γ, will be designated as “δ”. The distance (δ-ε) between this nucleotide δ and the above-described nucleotide ε will be designated as “Z” expressed in terms of the number of base(s). In
As conditions for permitting interaction between the fluorescent substance (d) and the guanine in the nucleotide ε when the nucleic acid probe complex in the present invention and the target nucleic acid (C) have hybridized with each other, the sum of X, Y and Z may preferably be 6 or smaller. The sum of X, Y and Z may be more preferably 4 or smaller, with 2 being most preferred, although it also depends on the length of the spacer connecting the fluorescent substance (d) and the nucleotide (a) labeled with the fluorescent substance (d).
Usable as the fluorescent substance (d) for labeling the fluorescent probe (A) in the present invention is a fluorescent substance (d) which changes in fluorescent character upon interaction with guanine. In the present invention, the term “fluorescent character” means fluorescence intensity, the expression “guanine and the fluorescent substance interact with each other to change the fluorescent character of the fluorescent substance” means that the fluorescence intensity of the fluorescent substance in a state that guanine and the fluorescent substance are not interacting each other is different from its fluorescence intensity in a state that they are interacting each other, and on the extent of this difference, no limitation shall be imposed. Further, the term “quenched or quenching” of fluorescence means that upon interaction of a fluorescent substance with guanine, the fluorescence intensity decreases compared with the fluorescence intensity when the fluorescent substance is not interacting with guanine, and on the extent of this decrease, no limitation shall be imposed.
Examples of fluorescent substances, which can be suitably used in the nucleic acid probe set according to the present invention, include fluorescein and its derivatives [e.g., fluorescein-4-isothiocyanate (FITC), tetrachlorofluorescein, hexachlorofluorescein, tetrabromosulfonefluorescein (TBSF), and derivatives thereof], EDANS (5-(2-aminoethyl)amino-1-naphthalenesulfonic acid), 6-JOE, Alexa Fluor 488 (Molecular Probe Corporation), Alexa Fluor 532 (Molecular Probe Corporation), Cy3 (Amersham Biosciences Corp.), Cy5 (Amersham Biosciences Corp.), Pacific Blue (Molecular Probe Corporation), rhodamine 6G (R6G) and its derivatives [e.g., carboxyrhodamine 6G (CR6G), tetramethylrhodamine (TMR), tetramethylrhodamine isothiocyanate (TMRITC), x-rhodamine, carboxytetramethylrhodamine (TAMRA)], Texas Red (Molecular Probe Corporation), BODIPY-FL (Molecular Probe Corporation), BODIPY-FL/C3 (Molecular Probe Corporation), BODIPY-FL/C6 (Molecular Probe Corporation), BODIPY-5-FAM (Molecular Probe Corporation), BODIPY-TMR (Molecular Probe Corporation), BODIPY-TR (Molecular Probe Corporation), BODIPY-R6G (Molecular Probe Corporation), BODIPY564 (Molecular Probe Corporation), and BODIPY581 (Molecular Probe Corporation).
Of these, the use of fluorescein, fluorescein-4-isothiocyanate, tetrachlorofluorescein, hexachlorofluorescein, tetrabromosulfonefluorescein, EDANS, 6-JOE, Alexa Fluor 488, Alexa Fluor 532, Pacific Blue, rhodamine 6G, carboxyrhodamine 6G, tetramethylrhodamine, carboxytetramethylrhodamine or BODIPY-FL is more preferred, and the use of BODIPY-FL is most preferred.
Concerning the fluorescent probe (A) for use in the nucleic acid probe set according to the present invention, its production can rely upon a custom oligonucleotide synthesis service company (for example, Tsukuba Oligo Service Co., Ltd., Ibaraki, Japan) or the like. No particular limitation is imposed on the method for labeling the fluorescent substance on the oligonucleotide, and a conventionally-known labeling method can be used (Nature Biotechnology, 14, 303-308, 1996; Applied and Environmental Microbiology, 63, 1143-1147, 1997; Nucleic Acids Research, 24, 4532-4535, 1996).
When desired to couple a fluorescent substance, for example, to the 5′-terminal nucleotide, it is necessary to first introduce, for example, —(CH2)n—SH as a spacer to a 5′-terminal phosphate group in a manner known per se in the art. As such a spacer, a commercial spacer can be used (for example, Midland Certified Reagent Company, U.S.A). In this case, n may stand for 3 to 8, with 6 being preferred. By coupling a fluorescent substance having SH reactivity or its derivative to the spacer, a fluorescently-labeled oligonucleotide can be obtained. The fluorescently-labeled oligonucleotide can be purified by reverse phase chromatography or the like to provide the fluorescent probe (A) for use in the present invention.
Further, a fluorescent substance can also be coupled to the 3′-terminal nucleotide of the oligonucleotide. In this case, it is necessary to introduce, for example, —(CH2)n—NH2 as a spacer to the OH group on the C at the 3′ site of ribose or deoxyribose. As such a spacer, a commercial spacer can also be used (for example, Midland Certified Reagent Company, U.S.A). As an alternative method, it is also possible to introduce a phosphate group to the OH group on the C at the 3′ site of ribose or deoxyribose and then to introduce, for example, —(CH2)n—SH as a spacer to the OH group in the phosphate group. In this case, n may stand for 3 to 8, with 4 to 7 being preferred.
By coupling a fluorescent substance, which has reactivity to an amino group or SH group, to the above-described spacer, an oligonucleotide labeled with the fluorescent substance can be synthesized. The oligonucleotide can be purified by reverse phase chromatography or the like to provide the fluorescent probe (A) for use in the present invention. When desired to introduce —(CH2)n—NH2 as a spacer, it is convenient to use a kit reagent (for example, Uni-link aminomodifier, Clonetech Laboratories, Inc.). The fluorescent substance can then be coupled to the oligonucleotide in a manner known per se in the art.
The nucleotide (a) in the fluorescent probe (A), said nucleotide (a) being labeled with the fluorescent substance, is not limited to one of both terminal nucleotides in the oligonucleotide, and a nucleotide other than both the terminal nucleotides can be labeled with the fluorescent substance (ANALYTICAL BIOCHEMISTRY, 225, 32-38, 1998).
The fluorescent probe (A) that constitutes the nucleic acid probe set according to the present invention can be prepared as described above. The preferred form of the fluorescent probe (A) is, however, one with the 5′-terminal or 3′-terminal nucleotide being labeled with the fluorescent substance (d), and more preferred is one with the 5′-terminal nucleotide being labeled with BODIPY-FL. As the base in the nucleotide labeled with the fluorescent substance (d), guanine or cytosine is preferred.
The fluorescent probe (A) that constitutes the nucleic acid probe set according to the present invention is only needed to have a base sequence which can hybridize with the fluorescent probe binding region (b1) in the binding probe (B), and no particular limitation is imposed on its base length. However, a length of 4 bases or less may not be preferred in that it may lead to a lower hybridization efficiency, and a length of 51 bases or more may not be preferred either in that it tends to form non-specific hybrids. Therefore, the fluorescent probe (A) may be preferably 5 to 50 bases long, more preferably 10 to 35 bases long, especially preferably 12 to 30 bases long.
The base sequence of the fluorescent probe (A) may include one or more nucleotides which are not complementary to the corresponding one or ones in the fluorescent probe binging region (b1), insofar as the fluorescent probe (A) can hybridize with the fluorescent probe binging region (b1) in the binding probe (B). Like the fluorescent probe (A) shown in
The target nucleic acid binding region (b2) in the binding probe (B) is only needed to have a base sequence which can hybridize with the target nucleic acid (C). The base length of the target nucleic acid binding region (b2) depends on the base length of the target nucleic acid. However, a length of 4 bases or less may not be preferred in that it may lead to a lower efficiency of hybridization with the target nucleic acid (C), and a length of 61 bases or more may not be preferred either in that it tends to form non-specific hybrids. Therefore, the target nucleic acid binding region (b2) may be preferably 5 to 60 bases long, more preferably 15 to 30 bases long. The target nucleic acid binding region (b2) may include a base sequence that forms no base pair with the target nucleic acid (C), insofar as it can hybridize with the target nucleic acid (C).
The nucleic acid probe set according to the present invention can be used in various analysis methods of nucleic acids. A description will hereinafter be made of an illustrative detection method of a target nucleic acid, which uses the nucleic acid probe set according to the present invention to determine whether or not the target nucleic acid exists in a solution.
A solution, which is to be detected for the target nucleic acid and will hereinafter be called “the detection sample”, is first serially diluted to prepare several kinds of solutions. The nucleic acid probe set according to the present invention, in other words, the fluorescent probe (A) and binding probe (B) are added in a constant amount to these serially-diluted detection samples. After the solutions are adjusted in temperature such that the thus-added nucleic acid probe complex in the present invention and the target nucleic acid can hybridize with each other, the solutions are measured for fluorescence intensity. The temperature, at which the probe complex in the present invention and the target nucleic acid are subjected to hybridization with each other, varies depending on the melting temperature (hereinafter called “Tm1”) of the hybridized complex of the nucleic acid probe complex in the present invention and the target nucleic acid and other solution conditions. However, the hybridization temperature may be preferably in a temperature range where sequence-specific hybridization takes place between the nucleic acid probe complex and the target nucleic acid but non-specific hybridization does not occur between them, more preferably Tm1 to (Tm1−40)° C., still more preferably Tm1 to (Tm1−20)° C., even still more preferably Tm1 to (Tm1−10)° C. As one example of such a preferred temperature, about 60° C. can be mentioned.
The melting temperature (hereinafter called “Tm2”) of the complex of the fluorescent probe and binding probe, which constitute the nucleic acid probe set according to the present invention, may be preferably higher than Tm1, with (Tm2−Tm1) of 5° C. or greater being more preferred, to assure the measurement of the fluorescence intensity.
When the target nucleic acid does not exist in the detection sample, a similar fluorescence intensity is observed from each of the serially-diluted detection samples. When the target nucleic acid exists in the detection sample, on the other hand, fluorescence from the fluorescent substance in the nucleic acid probe set according to the present invention is quenched by guanine in the nucleic acid which includes the target nucleic acid. The degree of this quenching varies by changing the ratio of the nucleic acid probe set to the target nucleic acid in the solution. By adding the nucleic acid probe set according to the present invention to detection samples, which has been serially diluted as mentioned above, and measuring their fluorescence intensities, it is, therefore, possible to determine the existence/non-existence of the target nucleic acid from the occurrence/non-occurrence of a fluorescence quenching and also to quantify the existing amounts of the target nucleic acid from the magnitudes of the fluorescence quenching.
The nucleic acid probe set according to the present invention can also be used in a real-time PCR method. When quantification of an amplification product is desired by using the nucleic acid probe set according to the present invention in the real-time PCR method, a base sequence to be amplified by PCR or a portion thereof is chosen as a target nucleic acid, and the base sequence of the target nucleic acid binding region (b2) in the binding probe (B) is determined such that the target nucleic acid binding region (b2) can hybridize with the target nucleic acid.
The nucleic acid probe set according to the present invention, which has been prepared as described above, is added to a PCR reaction solution, a PCR reaction is conducted, and the fluorescence intensity is measured in each cycle of PCR. When the target nucleic acid in the reaction solution is amplified through the PCR reaction, the fluorescence from the fluorescent substance in the nucleic acid probe set according to the present invention is quenched by guanine in a nucleic acid that includes the target nucleic acid. The amplification product by PCR can, therefore, be quantified from the fluorescence intensity and the degree of the fluorescence quenching.
The nucleic acid probe set according to the present invention can also be used in an analysis of a nucleic acid for a base sequence polymorphism. Examples of analyzable polymorphisms include a single nucleotide polymorphism, base substitution, base deletion, base insertion and the like with respect to a base sequence as a reference. One example of such an analysis method will be described hereinafter.
In this analysis method, the reference base sequence is used as a target nucleic acid (C), and a solution containing the target nucleic acid (C) and another solution containing a nucleic acid to be analyzed are prepared. After the nucleic acid probe set according to the present invention, that is, the binding probe (B), which has the target nucleic acid binding region (b2) designed to hybridize with the target nucleic acid (C), and the fluorescent probe (A) are added to the respective solutions, the added nucleic acid probe complex in the present invention is subjected to hybridization with the target nucleic acid (C) and the nucleic acid to be analyzed in the respective solutions, and the temperature dependences of fluorescence intensities are then measured. Described specifically, while changing the temperature of each solution from a low temperature to a high temperature, the fluorescence intensity is measured at each temperature.
A plot of the measurement results against temperature is called a “melting curve”. By differentiating the melting curve of the solution, which contains the target nucleic acid, with respect to temperature, Tm1 of the hybridized complex of the nucleic acid probe complex according to the present invention and the target nucleic acid (C) can be easily determined as a temperature that indicates an extreme value. Such a melting curve analysis can be performed by using a commercial program known well to those skilled in the art.
The fluorescence intensity of the solution, which contains the target nucleic acid (C), is reduced at a low temperature by the fluorescence quenching effect of guanine in the nucleic acid that includes the target nucleic acid (C). When the solution temperature is raised to around Tm1, however, the target nucleic acid dissociates from the nucleic acid probe complex in the present invention, the degree of fluorescence quenching decreases, and therefore, the fluorescence intensity suddenly increases. When there is, in the base sequence of the nucleic acid to be analyzed, a base sequence polymorphism, for example, a single nucleotide polymorphism, base substitution, base deletion, base insertion or the like with respect to the base sequence of the target nucleic acid, Tm1 of the hybridized complex of the nucleic acid to be analyzed and the nucleic acid probe complex in the present invention indicates a value lower than Tm1 of the hybridized complex of the target nucleic acid (C) and the nucleic acid probe complex in the present invention. By comparing the temperature dependence of the fluorescence intensity of the hybridized complex of the target nucleic acid and the nucleic acid probe complex in the present invention with the temperature dependence of the fluorescence intensity of the hybridized complex of the nucleic acid as the analysis target and the nucleic acid probe complex in the present invention, the nucleic acid as the analysis target can, therefore, be analyzed for a base sequence polymorphism with respect to the base sequence of the target nucleic acid. As such an analytical procedure, their melting curves may be compared with each other. However, the existence or non-existence of a mutation can be readily determined by differentiating the respective melting curves with respect to temperature, determining Tm1s as temperatures that give extreme values, and then comparing Tm1s.
When a nucleotide having a guanine base that applies the quenching effect to the fluorescent substance in the fluorescent probe has mutated in the base sequence of the nucleic acid as an analysis target, no decrease occurs in fluorescence intensity by the fluorescence quenching effect at any temperature so that the mutation can be specified from the melting curve.
In a melting curve analysis, it has heretofore been needed to prepare fluorescently-labeled, costly nucleic acid probes of different base sequences specifically for individual target nucleic acids, and therefore, a substantial time has been needed for their synthesis. The use of the nucleic acid probe set according to the present invention in a melting curve analysis can obviate the preparation of fluorescently-labeled, costly nucleic acid probes specifically for individual target nucleic acids, and therefore, can reduce the preparation time for the melting curve analysis and can more economically perform the melting curve analysis.
The above-described nucleic acid probe set according to the present invention is composed of the binding probe (B), which has the one fluorescent probe binding region (b1), and the one fluorescent probe (A). As an alternative, the nucleic acid probe set according to the present invention may have two fluorescent probe binding regions (b1) as shown in
The above-described nucleic acid probe set according to the present invention, in which the binding probe (B) has the two fluorescent probe binding regions of different base sequences, can be suitably used as a replacement for a conventionally-used AB probe in an ABC-PCR (Alternately Binding Probe Competitive PCR; see Tani et al., Analytical Chemistry, Preprint) method.
The ABC-PCR method disclosed by Tani et al. is a sort of competitive PCR method, and is a method that conducts a PCR reaction by adding a nucleic acid (hereinafter called “the internal standard nucleic acid”) and a nucleic acid probe (hereinafter called “the AB probe”) to a PCR reaction solution in addition to a nucleic acid that contains a base sequence to be amplified (hereinafter called “the amplification sequence”). The internal standard nucleic acid has a similar base sequence as the amplification sequence except that a portion of the base sequence has been replaced to guanine. The AB probe has a base sequence complementary to a portion of the amplification sequence and is labeled at opposite ends thereof with different fluorescent substances which are different in excitation wavelength and fluorescence wavelength. The AB probe is designed such that, when hybridized with the nucleic acid containing the amplification sequence, only one of the fluorescent substances is quenched by the guanine in the nucleic acid and that, when hybridized with the internal standard nucleic acid, both of the fluorescent substances are quenched by the guanine in the internal standard nucleic acid. An amplification product of the PCR reaction can, therefore, be quantified from the fluorescence intensities of the two kinds of fluorescent substances.
As fluorescently-labeled AB probes for use in the above-described conventional ABC-PCR method, different types of probes have to be used specifically for individual base sequences to be amplified. The use of nucleic acid probe sets according to the present invention in place of the above-described AB probes can obviate the need to prepare different types of fluorescently-labeled, costly fluorescent probes specifically for individual base sequences to be amplified, and therefore, can perform the ABC-PCR method more economically.
One example of nucleic acid probe sets according to the present invention, which are suited for use in such an ABC-PCR method, is illustrated in
The present invention will next be described more specifically based on examples. However, the following examples are merely illustrative of the present invention, and are not intended to be limiting the present invention.
Using a nucleic acid probe set for an oligonucleotide, which had the same base sequence as a portion of the human UCP1 gene, as a target nucleic acid (SEQ ID NO:1), a target nucleic acid detection test was performed. As is shown in
The binding probe and fluorescent probe both had a phosphate group at 3′ ends thereof. Syntheses of the target nucleic acid, binding probe and fluorescent probe were relied upon Tsukuba Oligo Services Co., Ltd. (Tsukuba, Japan).
Six kinds of target nucleic acid solutions were prepared by serially diluting the target nucleic acid in a PCR buffer (which contained 50 mM KCl, 10 mM Tris-HCl and 1.5 mM MgCl2; the concentrations were all final concentrations; pH 8.7) such that the final concentration of the target nucleic acid became 0, 0.1, 0.2, 0.3, 0.4 and 0.5 μM. To the respective target nucleic acid solutions, the fluorescent probe (final concentration: 0.05 μM) and binding probe (final concentration: 0.2 μM) were added. Each solution was measured at 60° C. for fluorescence intensity. For the measurement of fluorescence intensity, LightCycler® 480 (Roche Diagnostics K.K.) was used. The measurement results are shown in
It has been confirmed from
Prepared were five kinds of reaction solutions for real-time PCR, which contained 500 ng, 50 ng, 5 ng, 0.5 ng and 0.05 ng of a human genomic DNA sample (Promega K.K.), respectively, as a template DNA for PCR. Those reaction solutions each contained TITANIUM Taq DNA polymerase (Clonetech Laboratories, Inc.) as a DNA polymerase, four kinds of dNTPs (each at 0.2 mM final concentration), a forward primer (SEQ ID NO:4, final concentration: 0.5 μM), a reverse primer (SEQ ID NO:5, final concentration: 0.15 μM), a predetermined amount of TITANUM Taq PCR buffer (Clonetech Laboratories, Inc.), and a nucleic acid probe set according to the present invention.
The nucleic acid probe set according to the present invention was for a portion (SEQ ID NO:1) of the UCP1 gene in the human genome as a target nucleic acid, and was composed of a binding probe (SEQ ID NO:2; final concentration: 0.2 μM) and a fluorescent probe (final concentration: 0.05 μM). The binding probe had, on the side of a 5′-end thereof, (b1) a fluorescent probe binding region of a base sequence complementary to the fluorescent probe, and on the side of a 3′-end thereof, (b2) a target nucleic acid binding region of a base sequence complementary to the target nucleic acid. The fluorescent probe had the base sequence (SEQ ID NO:3), and was labeled at a 5′-terminal nucleotide thereof with BODIPY-FL (Molecular Probe Corporation). Each PCR reaction solution was prepared by adding sterilized water to bring its volume to 20 μL. A nucleic acid including the target nucleic acid was amplified by a PCR reaction as will be described hereinafter.
The binding probe and fluorescent probe both had a phosphate group at 3′ ends thereof. Synthesis of the nucleic acid probe was relied upon Tsukuba Oligo Service Co., Ltd. (Tsukuba, Japan), and syntheses of the forward primer and reverse primer were relied upon Nihon Gene Research Laboratories, Inc. (Sendai, Japan).
Using a real-time PCR system (LightCycler® 480, Roche Diagnostics K.K.), the reaction solutions were subjected to the following PCR reaction.
(1) Thermal denaturation step: 95° C., 120 seconds
(2) Thermal denaturation step: 95° C., 10 seconds
(3) Annealing step: 60° C., 20 seconds
(4) Extension step: 72° C., 10 seconds After the thermal reaction step (1), the steps (2) to (4) were repeated. In each annealing step (3), the fluorescence intensity was measured to determine the cycle number (hereinafter abbreviated as “Ct (cycle threshold) value”) in which the fluorescence intensity first decreased to a value of 95% or smaller of the fluorescence strength in the 5th cycle. It is to be noted that the Ct value is a value determined from a line drawn by connecting the fluorescence intensities in the respective PCR cycles.
A diagram of plots of Ct values (an average of two measurements, each) versus the respective amounts of the template DNA added initially is shown in
Using a nucleic acid probe set according to the present invention for the nucleic acid of 21 bases long (SEQ ID NO:1), which was the portion of the human UCP1 gene, as a target nucleic acid, a melting curve analysis of a complex of the nucleic acid probe set according to the present invention and the target nucleic acid was performed. The nucleic acid probe set was composed of a binding probe (SEQ ID NO:2) and a fluorescent probe. The binding probe had, on the side of a 5′-end thereof, a region of a base sequence complementary to the fluorescent probe, and on the side of a 3′-end thereof, a region of a base sequence complementary to the target nucleic acid (SEQ ID NO:1). The fluorescent probe had the base sequence (SEQ ID NO:3), and was labeled at a 5′-terminal nucleotide thereof with BODIPY-FL (Molecular Probe Corporation). Using, in place of the above-described target nucleic acid, a similar nucleic acid (SEQ IQ NO:6) as the above-described target nucleic acid except that the 17th base from the 5′-end had been substituted to adenine, another melting curve analysis was performed likewise. It is to be noted that in the subsequent part of Example 3, the target nucleic acid and the nucleic acid (SEQ ID NO:6) will be collectively called “the target nucleic acids”.
The binding probe and fluorescent probe both had a phosphate group at 3′ ends thereof. Syntheses of the target nucleic acids and nucleic acid probe were relied upon Tsukuba Oligo Services Co., Ltd. (Tsukuba, Japan).
Three kinds of solutions were provided, including solutions prepared by adding the target nucleic acid and the nucleic acid (SEQ ID NO:6) (each, to 0.1 μM final concentration) to portions of the PCR buffer which contained the nucleic acid probe set according to the present invention (the fluorescent probe (final concentration: 0.05 μM) and the binding probe (final concentration: 0.2 μM)), respectively, and a further solution which was a portion of the PCR buffer without addition of any of the target nucleic acids. The PCR buffer contained KCl, Tris-HCl and MgCl2 at final concentrations of 50 mM, 10 mM and 1.5 mM, respectively, and had pH 8.7. After each solution was maintained at 40° C. for 60 seconds to hybridize the nucleic acid probe set according to the present invention and, if any, the corresponding one of the target nucleic acids, the fluorescence intensity was measured while raising the solution temperature from 40° C. to 80° C. (the measurement was conducted 5 times at every Celsius degree). As a result, the melting curves shown in
As a result of the experiment, the performance of the melting curve analysis by the nucleic acid probe set according to the present invention made it possible to clearly determine, from the negative first differential curves of the melting curves indicated by D and E in
Using a nucleic acid probe set according to the present invention for a portion (SEQ ID NO:7) of the amoA gene coding an ammonia monooxygenase of an ammonium oxidizing bacteria (Nitrosomonas europaea (NBRC 14298)) as a target nucleic acid, an ABC-PCR experiment was performed, and the effectiveness of the nucleic acid probe set according to the present invention was evaluated.
The nucleic acid probe set for use in this ABC-PCR experiment was composed of one binding probe and two fluorescent probes as shown in
On the other hand, the fluorescent probe (A2-amoA) was designed to hybridize with the side of the 3′-end of the binding probe, and was an oligonucleotide of 15 bases long. The oligonucleotide had a base sequence (SEQ ID NO:10) and was labeled at a 3′-terminal nucleotide thereof with carboxytetramethylrhodamine (TAMRA).
Used as an internal standard nucleic acid in this example was a similar amoA gene as the amoA gene of the Nitrosomonas europaea (NBRC 14298), the latter amoA gene having the above-described target nucleic acid, except that the two bases on the side of the 3′-end (on an outer side), said two bases being located adjacent the 3′-end of the target nucleic acid, were replaced to guanine in a manner known per se in the art (see, for example, Higuchi et al., Nucleic Acids Res., 16, 7351-5367, 1988). The fluorescent probe (A1-amoA) was not quenched when hybridized as a nucleic acid probe complex with the target nucleic acid, but was quenched by the substituted guanine in the similar amoA gene when hybridized with the internal standard nucleic acid.
A PCR reaction solution used in the ABC-PCR experiment contained a predetermined amount of TITANIUM Taq DNA polymerase (Clonetech Laboratories, Inc.) as a DNA polymerase, a predetermined amount of TITANIUM Taq PCR buffer (Clonetech Laboratories, Inc.), dATP, dCTP and dGTP (each, final concentration: 200 μM), dUTP (Roche Diagnostics K.K.) (final concentration: 600 μM), a forward primer (SEQ ID NO: 11, final concentration: 0.1 μM), a reverse primer (SEQ ID NO: 12, final concentration: 1 μM), the binding probe (final concentration: 0.1 μM) and the two types of fluorescent probes (each, final concentration: 0.15 μM), uracil-DNA glycosylase (0.25 U, Roche Diagnostics K.K.) for avoiding contamination by an amplification product, and 103 copies of the internal standard nucleic acid. A PCR reaction solution free of the above-descried target nucleic acid and PCR reaction solutions containing 10, 100, 300, 1,000, 3,000, 10,000 and 100,000 copies of the above described target nucleic acid, respectively, were prepared, and sterilized water was added to the respective PCR reaction solutions to bring their volumes to 25 μL.
In the above-described sequences, h means A, C or T, y means C or T, k means G or T, and s means G or C.
Using Bio101 FastDNA spin kit (Qbiogene, Inc.), a DNA was extracted from 0.5 g (wet weight) of an ammonium oxidizing bacteria (Nitrosomonas europaea (NBRC 14928)) (purchased from Biological Research Center, National Institute of Technology and Evaluation (NITE)) cultured in NBRC liquid medium. Using Microcon YM-50 (Millipore Corporation), the DNA was purified. The purified DNA was used as the above-described target nucleic acid.
To avoid contamination, during the preparation of the PCR reaction solutions, the solutions were maintained at room temperature and were subjected to a glycosylase reaction by uracil-DNA glycosylase. After the preparation of the solutions, they were subjected to the following PCR reaction.
(1) Thermal denaturation step: 95° C., 120 seconds
(2) Thermal denaturation step: 95° C., 45 seconds
(3) Annealing step: 55° C., 60 seconds
(4) Extension step: 72° C., 45 seconds
(5) Extension step: 72° C., 45 seconds
After the thermal reaction step (1), the steps (2) to (4) were repeated 60 cycles, and subsequently, the extension step (5) was conducted. As a thermal cycler for the PCR reaction, iCycler (Bio-Rad Laboratories, Inc.) was used.
After completion of the PCR reaction, the fluorescence intensity of each solution was measured at 95° C. and 55° C. by using SmartCycler® (Cepheid). The fluorescence intensity of the fluorescence probe A1-amoA (hereinafter called “the fluorescence intensity A1”) was measured in an excitation wavelength range of 450 to 495 nm and in a detection wavelength range of 505 to 537 nm, while the fluorescence intensity of the fluorescence probe A2-amoA (hereinafter called “the fluorescence intensity A2”) was measured in an excitation wavelength range of 527 to 555 nm and in a detection wavelength range of 565 to 605 nm.
The resulting fluorescence intensities were introduced into the following formula (1) to determine the corrected fluorescence intensity values with respect to the seven kinds of reaction solutions that contained the target nucleic acid.
Corrected fluorescence intensity value=[(GU,55/GU,95)−(G55/G95)]/[(RU,55/RU,95)−(R55/R95)] (1)
where,
GU,55: Fluorescence intensity A1 at 55° C. of the reaction solution free of the target nucleic acid.
GU,95: Fluorescence intensity A1 at 95° C. of the reaction solution free of the target nucleic acid.
G55: Fluorescence intensity A1 at 55° C. of the reaction solution containing the target nucleic acid.
G95: Fluorescence intensity A1 at 95° C. of the reaction solution containing the target nucleic acid.
RU,55: Fluorescence intensity A2 at 55° C. of the reaction solution containing the target nucleic acid.
RU,95: Fluorescence intensity A2 at 95° C. of the reaction solution containing the target nucleic acid.
R55: Fluorescence intensity A2 at 55° C. of the reaction solution free of the target nucleic acid.
R95: Fluorescence intensity A2 at 95° C. of the reaction solution free of target nucleic acid.
A diagram of the resulting corrected fluorescence intensity values as plotted on a semi-logarithmic graph, in which the copy number of the target nucleic acid before the PCR reaction are plotted along the abscissas, is shown in
Using this relational expression as a calibration curve, an experiment was next conducted to calculate the copy numbers of the target nucleic acid, which were contained in reaction solutions before a PCR reaction, from the fluorescence intensities of the reaction solutions after the ABC-PCR reaction.
Prepared were three kinds of PCR reaction solutions, which were similar to the above-described ABC-PCR reaction solution except for the number of copies of the target nucleic acid. As the reaction solutions, solutions containing 0, 2,000 and 6,000 copies of the target nucleic acid, respectively, were prepared as many as 5 samples per solution. The three kinds of PCR reaction solutions were subjected to a 60-cycle PCR reaction as in the above-described ABC-PCR experiment, the fluorescence intensities after the reaction were introduced into the formula (1) to determine the corrected fluorescence intensity values, and by applying these values to the above-described calibration curve, the copy numbers of the target nucleic acid before the PCR reaction were calculated. The results are shown in Table 1.
As is clearly envisaged from Table 1, the calculated value of the number of copies of the target nucleic acid before the PCR reaction as calculated from the fluorescence intensity of each reaction solution after the PCR reaction conformed closely to the number of copies of the target nucleic acid actually used. This result indicates that similar to the conventionally-used AB probes, the nucleic acid probe set according to the present invention can also be used in an ABC-PCR experiment and has high reliability.
The present invention can provide a nucleic acid probe set which can specifically analyze a target nucleic acid. The nucleic acid probe set according to the present invention does not require preparing a fluorescently-labeled, costly nucleic acid probe specifically for every target nucleic acid to be analyzed, and therefore, has an advantage that a nucleic acid probe for a target nucleic acid can be prepared at low cost and in a short time compared with the conventional nucleic acid probes. The nucleic acid probe set according to the present invention can be applied to the detection, quantification and polymorphism analysis of nucleic acids, the detection of mutations, and the like in fields such as medical science, molecular biology and agricultural science.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2008/063638 | 7/30/2008 | WO | 00 | 4/15/2011 |
